MX2022011888A - Tratamiento de trastornos respiratorios. - Google Patents

Tratamiento de trastornos respiratorios.

Info

Publication number
MX2022011888A
MX2022011888A MX2022011888A MX2022011888A MX2022011888A MX 2022011888 A MX2022011888 A MX 2022011888A MX 2022011888 A MX2022011888 A MX 2022011888A MX 2022011888 A MX2022011888 A MX 2022011888A MX 2022011888 A MX2022011888 A MX 2022011888A
Authority
MX
Mexico
Prior art keywords
treatment
respiratory disorders
disorders
respiratory
compounds
Prior art date
Application number
MX2022011888A
Other languages
English (en)
Inventor
Martijn Fenaux
Christopher T Jones
Erin K Quirk
Original Assignee
Terns Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Terns Inc filed Critical Terns Inc
Publication of MX2022011888A publication Critical patent/MX2022011888A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0043—Nose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Otolaryngology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

En la presente descripción se proporcionan compuestos para su uso en el tratamiento de trastornos respiratorios.
MX2022011888A 2020-03-25 2021-03-25 Tratamiento de trastornos respiratorios. MX2022011888A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202062994617P 2020-03-25 2020-03-25
PCT/US2021/024239 WO2021195435A1 (en) 2020-03-25 2021-03-25 Treatment of respiratory disorders

Publications (1)

Publication Number Publication Date
MX2022011888A true MX2022011888A (es) 2023-03-06

Family

ID=77892404

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022011888A MX2022011888A (es) 2020-03-25 2021-03-25 Tratamiento de trastornos respiratorios.

Country Status (13)

Country Link
US (1) US20230127498A1 (es)
EP (1) EP4125968A4 (es)
JP (1) JP2023529255A (es)
KR (1) KR20220158022A (es)
CN (1) CN115666577A (es)
AU (1) AU2021241646A1 (es)
BR (1) BR112022019168A2 (es)
CA (1) CA3176881A1 (es)
CL (1) CL2022002589A1 (es)
IL (1) IL296816A (es)
MX (1) MX2022011888A (es)
PE (1) PE20230997A1 (es)
WO (1) WO2021195435A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113149957A (zh) * 2020-01-23 2021-07-23 轶诺(浙江)药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用
CN116615416A (zh) 2020-08-25 2023-08-18 伊莱利利公司 Ssao抑制剂的多晶型物

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201115853D0 (en) * 2011-09-14 2011-10-26 Proximagen Ltd New enzyme inhibitor compounds
PL2844637T3 (pl) * 2012-05-02 2018-09-28 Boehringer Ingelheim International Gmbh Podstawione 3-haloalliloaminowe inhibitory ssao i ich zastosowania
GB201304527D0 (en) * 2013-03-13 2013-04-24 Proximagen Ltd New compounds
GB201513115D0 (en) * 2015-07-24 2015-09-09 Proximagen Ltd New therapeutic compound and use in therapy
WO2018027892A1 (en) * 2016-08-12 2018-02-15 Eli Lilly And Company Amino pyrimidine ssao inhibitors
US20210212968A1 (en) * 2016-10-19 2021-07-15 Boehringer Ingelheim International Gmbh Combinations comprising an ssao/vap-1 inhibitor and a sglt2 inhibitor, uses thereof
US20200087248A1 (en) * 2017-04-28 2020-03-19 Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. Fluoroallylamine Derivative And Use Thereof
CN109988109B (zh) * 2017-12-29 2020-12-29 广东东阳光药业有限公司 抑制ssao/vap-1的胺类化合物及其用途
US20210238192A1 (en) * 2018-06-29 2021-08-05 Blade Therapeutics, Inc. Vascular adhesion protein-1 (vap-1) modulators and therapeutic uses thereof
CN110938059A (zh) * 2018-09-25 2020-03-31 上海轶诺药业有限公司 胺基脲敏感性胺氧化酶抑制剂制备及其应用

Also Published As

Publication number Publication date
EP4125968A4 (en) 2024-04-10
KR20220158022A (ko) 2022-11-29
IL296816A (en) 2022-11-01
CA3176881A1 (en) 2021-09-30
CL2022002589A1 (es) 2023-03-31
BR112022019168A2 (pt) 2022-11-01
JP2023529255A (ja) 2023-07-10
PE20230997A1 (es) 2023-06-26
CN115666577A (zh) 2023-01-31
US20230127498A1 (en) 2023-04-27
AU2021241646A1 (en) 2022-11-24
WO2021195435A1 (en) 2021-09-30
EP4125968A1 (en) 2023-02-08

Similar Documents

Publication Publication Date Title
MX2022010082A (es) Triptaminas especificas para usarse en el tratamiento de trastornos de estado de animo.
MX2019012818A (es) Metodos para mejorar la memoria y la cognicion y para el tratamiento de trastornos de la memoria y cognitivos.
WO2020163823A8 (en) Therapeutic agents and methods of treatment
EA202192122A1 (ru) Соединения, обладающие активностью индуцирования ферроптоза, и способы их применения
MX2021008191A (es) Antagonistas del péptido relacionado con el gen de calcitonina (cgrp) para el tratamiento de la irrupción de migraña.
MX2023007212A (es) Formulaciones de pulverizacion de epinefrina.
MX2020008680A (es) Terapia de combinacion con apilimod y agentes glutamatergicos.
CR20220626A (es) Compuestos para el tratamiento de enfermedades y trastornos asociados a braf
MX2022011888A (es) Tratamiento de trastornos respiratorios.
MX2021011507A (es) Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
MX2019015207A (es) Compuestos para tratar el cancer de ovario.
MX2023004156A (es) Terapia combinada para el tratamiento del cancer.
ZA202300875B (en) Kat6 inhibitor methods and combinations for cancer treatment
MX2021015770A (es) Inhibidores macrociclicos de mcl-1.
MX2021011488A (es) Compuestos y usos de estos.
MX2023008193A (es) Procedimientos para tratar el cáncer.
MX2023010711A (es) Fenalquilaminas y métodos de preparación y uso de las mismas.
MX2022006853A (es) Macrociclos para uso en el tratamiento de enfermedades.
JOP20210245A1 (ar) طرق لعلاج الداء النشواني من النوع خفيف السلسلة
MX2020008881A (es) Métodos de tratamiento contra el cáncer que comprenden inhibidores de chk1.
MX2022000545A (es) Inhibidores de enzimas.
MX2021002652A (es) Uso de inhibidores de caseina-cinasa 1 para el tratamiento de enfermedades vasculares.
MX2021003160A (es) Combinaciones de inhibidores de tgfbeta e inhibidores de cdk para el tratamiento de cancer de mama.
MX2023006542A (es) Inhibidores de la vía cinasa jano 1 (jak1) para el tratamiento del vitiligo.
MX2022005250A (es) Combinaciones terapeuticas de acalabrutinib y capivasertib para tratar neoplasias malignas de linfocitos b.